Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer

Ulrich Peter Rohr, Nina Rehfeld, Helene Geddert, Lucy Pflugfelder, Ingmar Bruns, Judith Neukirch, Astrid Rohrbeck, Hans J. Grote, Ulrich G. Steidl, Roland Fenk, Bertram Opalka, Helmut E. Gabbert, Ralf Kronenwett, Rainer Haas

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: The fragile histidine triad protein (FHIT) is a putative tumor suppressor in patients with lung cancer. In this study, we examined the prognostic value of FHIT expression for survival in patients with small cell lung cancer (SCLC). Experimental Design: As assessed by immunohistochemistry using formalin-fixed, paraffin-embedded tissue sections, tumors of 225 patients with SCLC were retrospectively evaluated for FHIT expression. The influence of FHIT staining intensities as well as the proportion of FHIT-positive cells within a tumor was taken into consideration for univariate and multivariate survival analysis. Results: FHIT expression was observed in 61.8% of the SCLC tumors. Lack of FHIT was significantly associated with a shorter survival time for the patients with a median of 157 ± 18 days compared with 210 ± 18 days for those patients with FHIT-positive tumors (P = 0.0061). Furthermore, the proportion of FHIT-positive cells within the tumor was related to survival. Patients with tumors of <25% FHIT-positive cells had the worst survival of 155 ± 21 days compared with 217 ± 19 days for patients with a proportion of ≥25% of FHIT-expressing tumor cells (P = 0.0016). In contrast to the proportion of FHIT-positive cells within the tumor, no significant difference in survival was observed when different FHIT staining intensities (weak versus strong) were considered (median survival of 208 ± 17 versus 234 ± 34 days, P = 0.665). Multivariate analysis using Cox regression including 11 variables confirmed the prognostic significance of FHIT expression next to performance status, tumor stage, and lactate dehydrogenase. Conclusion: The presence of FHIT was correlated with a better prognosis for patients with SCLC.

Original languageEnglish (US)
Pages (from-to)180-185
Number of pages6
JournalClinical Cancer Research
Volume11
Issue number1
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Neoplasms
Survival
fragile histidine triad protein
Multivariate Analysis
Staining and Labeling
Survival Analysis
L-Lactate Dehydrogenase
Paraffin
Formaldehyde
Lung Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rohr, U. P., Rehfeld, N., Geddert, H., Pflugfelder, L., Bruns, I., Neukirch, J., ... Haas, R. (2005). Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer. Clinical Cancer Research, 11(1), 180-185.

Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer. / Rohr, Ulrich Peter; Rehfeld, Nina; Geddert, Helene; Pflugfelder, Lucy; Bruns, Ingmar; Neukirch, Judith; Rohrbeck, Astrid; Grote, Hans J.; Steidl, Ulrich G.; Fenk, Roland; Opalka, Bertram; Gabbert, Helmut E.; Kronenwett, Ralf; Haas, Rainer.

In: Clinical Cancer Research, Vol. 11, No. 1, 01.01.2005, p. 180-185.

Research output: Contribution to journalArticle

Rohr, UP, Rehfeld, N, Geddert, H, Pflugfelder, L, Bruns, I, Neukirch, J, Rohrbeck, A, Grote, HJ, Steidl, UG, Fenk, R, Opalka, B, Gabbert, HE, Kronenwett, R & Haas, R 2005, 'Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer', Clinical Cancer Research, vol. 11, no. 1, pp. 180-185.
Rohr UP, Rehfeld N, Geddert H, Pflugfelder L, Bruns I, Neukirch J et al. Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer. Clinical Cancer Research. 2005 Jan 1;11(1):180-185.
Rohr, Ulrich Peter ; Rehfeld, Nina ; Geddert, Helene ; Pflugfelder, Lucy ; Bruns, Ingmar ; Neukirch, Judith ; Rohrbeck, Astrid ; Grote, Hans J. ; Steidl, Ulrich G. ; Fenk, Roland ; Opalka, Bertram ; Gabbert, Helmut E. ; Kronenwett, Ralf ; Haas, Rainer. / Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer. In: Clinical Cancer Research. 2005 ; Vol. 11, No. 1. pp. 180-185.
@article{64c566d69b0648ce83c1549cb354c112,
title = "Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer",
abstract = "Purpose: The fragile histidine triad protein (FHIT) is a putative tumor suppressor in patients with lung cancer. In this study, we examined the prognostic value of FHIT expression for survival in patients with small cell lung cancer (SCLC). Experimental Design: As assessed by immunohistochemistry using formalin-fixed, paraffin-embedded tissue sections, tumors of 225 patients with SCLC were retrospectively evaluated for FHIT expression. The influence of FHIT staining intensities as well as the proportion of FHIT-positive cells within a tumor was taken into consideration for univariate and multivariate survival analysis. Results: FHIT expression was observed in 61.8{\%} of the SCLC tumors. Lack of FHIT was significantly associated with a shorter survival time for the patients with a median of 157 ± 18 days compared with 210 ± 18 days for those patients with FHIT-positive tumors (P = 0.0061). Furthermore, the proportion of FHIT-positive cells within the tumor was related to survival. Patients with tumors of <25{\%} FHIT-positive cells had the worst survival of 155 ± 21 days compared with 217 ± 19 days for patients with a proportion of ≥25{\%} of FHIT-expressing tumor cells (P = 0.0016). In contrast to the proportion of FHIT-positive cells within the tumor, no significant difference in survival was observed when different FHIT staining intensities (weak versus strong) were considered (median survival of 208 ± 17 versus 234 ± 34 days, P = 0.665). Multivariate analysis using Cox regression including 11 variables confirmed the prognostic significance of FHIT expression next to performance status, tumor stage, and lactate dehydrogenase. Conclusion: The presence of FHIT was correlated with a better prognosis for patients with SCLC.",
author = "Rohr, {Ulrich Peter} and Nina Rehfeld and Helene Geddert and Lucy Pflugfelder and Ingmar Bruns and Judith Neukirch and Astrid Rohrbeck and Grote, {Hans J.} and Steidl, {Ulrich G.} and Roland Fenk and Bertram Opalka and Gabbert, {Helmut E.} and Ralf Kronenwett and Rainer Haas",
year = "2005",
month = "1",
day = "1",
language = "English (US)",
volume = "11",
pages = "180--185",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - Prognostic relevance of fragile histidine triad protein expression in patients with small cell lung cancer

AU - Rohr, Ulrich Peter

AU - Rehfeld, Nina

AU - Geddert, Helene

AU - Pflugfelder, Lucy

AU - Bruns, Ingmar

AU - Neukirch, Judith

AU - Rohrbeck, Astrid

AU - Grote, Hans J.

AU - Steidl, Ulrich G.

AU - Fenk, Roland

AU - Opalka, Bertram

AU - Gabbert, Helmut E.

AU - Kronenwett, Ralf

AU - Haas, Rainer

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Purpose: The fragile histidine triad protein (FHIT) is a putative tumor suppressor in patients with lung cancer. In this study, we examined the prognostic value of FHIT expression for survival in patients with small cell lung cancer (SCLC). Experimental Design: As assessed by immunohistochemistry using formalin-fixed, paraffin-embedded tissue sections, tumors of 225 patients with SCLC were retrospectively evaluated for FHIT expression. The influence of FHIT staining intensities as well as the proportion of FHIT-positive cells within a tumor was taken into consideration for univariate and multivariate survival analysis. Results: FHIT expression was observed in 61.8% of the SCLC tumors. Lack of FHIT was significantly associated with a shorter survival time for the patients with a median of 157 ± 18 days compared with 210 ± 18 days for those patients with FHIT-positive tumors (P = 0.0061). Furthermore, the proportion of FHIT-positive cells within the tumor was related to survival. Patients with tumors of <25% FHIT-positive cells had the worst survival of 155 ± 21 days compared with 217 ± 19 days for patients with a proportion of ≥25% of FHIT-expressing tumor cells (P = 0.0016). In contrast to the proportion of FHIT-positive cells within the tumor, no significant difference in survival was observed when different FHIT staining intensities (weak versus strong) were considered (median survival of 208 ± 17 versus 234 ± 34 days, P = 0.665). Multivariate analysis using Cox regression including 11 variables confirmed the prognostic significance of FHIT expression next to performance status, tumor stage, and lactate dehydrogenase. Conclusion: The presence of FHIT was correlated with a better prognosis for patients with SCLC.

AB - Purpose: The fragile histidine triad protein (FHIT) is a putative tumor suppressor in patients with lung cancer. In this study, we examined the prognostic value of FHIT expression for survival in patients with small cell lung cancer (SCLC). Experimental Design: As assessed by immunohistochemistry using formalin-fixed, paraffin-embedded tissue sections, tumors of 225 patients with SCLC were retrospectively evaluated for FHIT expression. The influence of FHIT staining intensities as well as the proportion of FHIT-positive cells within a tumor was taken into consideration for univariate and multivariate survival analysis. Results: FHIT expression was observed in 61.8% of the SCLC tumors. Lack of FHIT was significantly associated with a shorter survival time for the patients with a median of 157 ± 18 days compared with 210 ± 18 days for those patients with FHIT-positive tumors (P = 0.0061). Furthermore, the proportion of FHIT-positive cells within the tumor was related to survival. Patients with tumors of <25% FHIT-positive cells had the worst survival of 155 ± 21 days compared with 217 ± 19 days for patients with a proportion of ≥25% of FHIT-expressing tumor cells (P = 0.0016). In contrast to the proportion of FHIT-positive cells within the tumor, no significant difference in survival was observed when different FHIT staining intensities (weak versus strong) were considered (median survival of 208 ± 17 versus 234 ± 34 days, P = 0.665). Multivariate analysis using Cox regression including 11 variables confirmed the prognostic significance of FHIT expression next to performance status, tumor stage, and lactate dehydrogenase. Conclusion: The presence of FHIT was correlated with a better prognosis for patients with SCLC.

UR - http://www.scopus.com/inward/record.url?scp=19944427560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944427560&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 180

EP - 185

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -